L 759274Alternative Names: NK1 antagonist - Merck; Substance P antagonist - Merck
Latest Information Update: 20 Jun 2012
At a glance
- Originator Merck & Co
- Class Antidepressants
- Mechanism of Action Neurokinin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Major depressive disorder